See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report for: BCLI
Shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price target of $7.50 for the company and are predicting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also assigned Brainstorm Cell Therapeutics an industry rank of 115 out of 265 based on the ratings given to related companies.
Separately, Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of Brainstorm Cell Therapeutics in a report on Wednesday, January 20th.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) traded up 1.38% during trading on Thursday, reaching $2.20. 69,377 shares of the company’s stock traded hands. The firm’s market cap is $40.70 million. Brainstorm Cell Therapeutics has a 12 month low of $1.90 and a 12 month high of $4.37. The firm has a 50 day moving average price of $2.55 and a 200-day moving average price of $2.59.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (NASDAQ:BCLI), Multiple Sclerosis and Parkinson’s disease, among others.
Source – Vista Voice
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Hot small cap stocks
small cap stock picks
FDA approval stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news